Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu-Bu-Mel-E conditioning for lymphoid malignancies undergoing allo-HSCT
NCT04897139Phase 2Unknown
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jan 2021
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, busulfan, melphalan, etoposide in lymphoid neoplasm, sponsored by Shanghai Jiao Tong University School of Medicine. Status: unknown.
02
Drugs
fludarabinebusulfanmelphalanetoposide
03
Conditions
lymphoid neoplasm
Beyond the preview
Go deeper on NCT04897139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04897139.